Allurion Technologies, Inc. Common Stock (ALUR)
2.3600
+0.00 (0.00%)
NYSE · Last Trade: May 14th, 6:08 AM EDT
Detailed Quote
Previous Close | 2.360 |
---|---|
Open | - |
Bid | 2.840 |
Ask | 2.870 |
Day's Range | N/A - N/A |
52 Week Range | 2.150 - 88.75 |
Volume | 909,199 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 251,921 |
Chart
News & Press Releases
Via Benzinga · May 14, 2025
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · May 13, 2025
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass preservation.
By Allurion Technologies, Inc. · Via Business Wire · May 13, 2025
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.
By Allurion Technologies, Inc. · Via Business Wire · May 5, 2025
Via Benzinga · April 16, 2025
Via Benzinga · April 7, 2025
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the “Special Meeting”), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM.
By Allurion Technologies, Inc. · Via Business Wire · April 3, 2025
Via Benzinga · March 31, 2025
Allurion attributed the fall in Q4 revenue to a temporary suspension of sales in France, coupled with macroeconomic headwinds in certain markets, which caused lower reorder rates.
Via Stocktwits · March 26, 2025
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.
By Allurion Technologies, Inc. · Via Business Wire · March 26, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 21, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 21, 2025
Via Benzinga · March 21, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · March 21, 2025
Via Benzinga · March 21, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · March 21, 2025
Via Benzinga · March 21, 2025
Via Benzinga · March 21, 2025
U.S. stock futures declined on Friday after tumbling in trade on Thursday. Futures of all four indices were lower in premarket trading.
Via Benzinga · March 21, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.
By Allurion Technologies, Inc. · Via Business Wire · March 20, 2025